Volume 26, Issue 2
February 2024
Cover image
Cover image
Scheme shown in Figure 1 of the article by Chen et al. “Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?” beginning on p. 211.
ISSN 1522-8517
EISSN 1523-5866
Issue navigation
Volume 26, Issue 2, February 2024
Breaking News Editorials
A 34-gene expression biomarker predicts meningioma outcomes and radiotherapy responses
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 207–208, https://doi.org/10.1093/neuonc/noad212
Oncolytic immunoactivation associates with survival in a glioblastoma clinical trial
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 209–210, https://doi.org/10.1093/neuonc/noad216
Reviews
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 211–225, https://doi.org/10.1093/neuonc/noad211
Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 226–235, https://doi.org/10.1093/neuonc/noad170
Basic and Translational Investigations
Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 236–250, https://doi.org/10.1093/neuonc/noad199
Branched-chain amino acid transaminase 1 regulates glioblastoma cell plasticity and contributes to immunosuppression
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 251–265, https://doi.org/10.1093/neuonc/noad190
NLGN4X TCR transgenic T cells to treat gliomas
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 266–278, https://doi.org/10.1093/neuonc/noad172
Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 279–294, https://doi.org/10.1093/neuonc/noad198
Integrating single-cell and spatial transcriptomics reveals endoplasmic reticulum stress-related CAF subpopulations associated with chordoma progression
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 295–308, https://doi.org/10.1093/neuonc/noad173
SRRM4-mediated REST to REST4 dysregulation promotes tumor growth and neural adaptation in breast cancer leading to brain metastasis
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 309–322, https://doi.org/10.1093/neuonc/noad175
Clinical Investigations
Glioma genetic profiles associated with electrophysiologic hyperexcitability
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 323–334, https://doi.org/10.1093/neuonc/noad176
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 335–347, https://doi.org/10.1093/neuonc/noad185
Pediatric Neuro-Oncology
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 348–361, https://doi.org/10.1093/neuonc/noad174
Radiotherapy-induced vascular cognitive impairment 20 years after childhood brain tumor
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 362–373, https://doi.org/10.1093/neuonc/noad186
Neuroimaging
Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 374–386, https://doi.org/10.1093/neuonc/noad177
Epidemiology
Brain tumors in United States military veterans
Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 387–396, https://doi.org/10.1093/neuonc/noad182
Society News
Forthcoming Meetings
Neuro-Oncology, Volume 26, Issue 2, February 2024, Page 397, https://doi.org/10.1093/neuonc/noae003
